Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
It protects liver cells that are exposed to toxins on a daily basis
Contrave may be beneficial for individuals struggling with cravings and emotional eating triggered by anxiety and stress factors whereas Wegovys ability to induce prolonged feelings of fullness could result in sustainable weight loss outcomes in the long run
Protein at every meal Protein helps preserve muscle mass during weight loss, which is especially important because hypothyroidism can already contribute to muscle weakness
2020;9(Suppl 2):S149-S159
Patients with an underactive thyroid or certain other medical conditions should consult their provider
